In what’s shaping up to be a red-letter week for Gardasil, Merck & Co. has simultaneously opened a massive new manufacturing facility for the human papillomavirus (HPV) shot in the U.S. | In ...

In a significant blow to plaintiffs suing over the HPV vaccine Gardasil, a federal judge on Tuesday sided with Merck & Co. Inc. on its implied preemption defense.

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

Merck said on Tuesday it would not ship its HPV vaccine Gardasil in China until at least the middle of this year due to weak discretionary spending, a move that dented its full-year forecast and ...

The continued decline of Merck & Co.’s HPV vaccine Gardasil in China has come to a head as the New Jersey drug giant is halting shipments to the world’s second-most populous country.

Merck & Co pauses Gardasil vaccine shipments to China, lowers sales outlook ...

Merck Halts China Gardasil Shipments, Boosting Investor Pain. Merck & Co. shares tumbled after the company halted shipments to China of its cancer-preventing Gardasil vaccine, a dramatic escalation to ...

Merck said it had stopped Gardasil shipments to China from this month. The company has previously said China’s anti-bribery and anti-corruption drive had also hurt sales of the vaccine.

Merck & Co Inc (MRK) Key Morningstar Metrics for Merck. Fair Value Estimate: $111.00; ... Gardasil was 13% of Merck’s sales in 2024, and roughly half of Gardasil sales tie to China.

On Thursday, Merck & Co Inc (NYSE:MRK) reported third-quarter sales of $16.66 billion, up 4% year over year, beating the consensus of $16.47 billion. Merck reported a decline of 11% in sales of ...

Keytruda sales surged 17% YoY to $7.43B, while Gardasil sales dropped 11% to $2.31B due to reduced demand in China. Merck's Q3 sales reached $16.7 billion, a 4% YoY increase, beating the $16.5 ...

(Reuters) -Merck & Co said on Thursday that weak sales of Gardasil in China are likely to carry over into 2025 as the vaccine's distributor there reduces inventories amid low demand, and the U.S.